Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Strong underlying insulin market growth and sustained global volume market share Slide 42 Global insulin market Device penetration Modern insulin penetration¹ Novo Nordisk Global modern insulin³ volume market shares Sanofi - Eli Lilly tMU Penetration 500 CAGR volume²: 4.6% 100% 60% CAGR value²: 20.4% 50% 400 80% 40% 45% 35% 300 +60% Modern insulin¹ 30% 200 - 40% 19% 20% 100 20% Human insulin 10% 0% 0% Aug 2011 1 Includes new-generation insulin 2 CAGR for 5-year period Note: Data is sensitive to changes in IMS data collection and reporting methodology Source: IMS Monthly MAT August, 2016 volume and value (DKK) figures Aug 2016 Aug 2011 Aug 2016 3 Includes new-generation insulin Note: Data is sensitive to changes in IMS data collection and reporting methodology, does not add up to 100% due to other players changing diabetes® Source: IMS Monthly MAT August, 2016 volume figures novo nordisk

View entire presentation